Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial

BACKGROUND: Anticoagulation in patients with malignancy and atrial fibrillation is challenging because of enhanced risks for thrombosis and bleeding and the frequent need for invasive procedures. Data on direct oral antagonists in such patients are sparse. METHODS AND RESULTS: The ENGAGE AF‐TIMI 48...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanola, Christina L., Ruff, Christian T., Murphy, Sabina A., Jin, James, Duggal, Anil, Babilonia, Noe A., Sritara, Piyamitr, Mercuri, Michele F., Kamphuisen, Pieter W., Antman, Elliott M., Braunwald, Eugene, Giugliano, Robert P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201390/
https://www.ncbi.nlm.nih.gov/pubmed/30369307
http://dx.doi.org/10.1161/JAHA.118.008987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201390/
https://www.ncbi.nlm.nih.gov/pubmed/30369307
http://dx.doi.org/10.1161/JAHA.118.008987

Ejemplares similares